WCLC 2023| Dr. Wang Jie Awarded the 2023 Small Cell Lung Cancer Heine H. Hansen Award

WCLC 2023| Dr. Wang Jie Awarded the 2023 Small Cell Lung Cancer Heine H. Hansen Award

2024.01.19
The International Association for the Study of Lung Cancer (IASLC) annually presents several awards to clinical physicians and researchers who have made significant contributions to the treatment of lung cancer patients. Awardees are invited to receive their awards at the World Conference on Lung Cancer (WCLC) and give speeches in their respective fields. At the WCLC 2023 conference, these awards were presented for the first time in a dedicated plenary session titled "Plenary Session 2: IASLC Lectureship Award Presentations," jointly hosted by IASLC CEO Karen Kelly and IASLC President Heather Wakelee. The Lectureship awards are presented to members from various fields, including radiation oncology, medical oncology, small cell lung cancer, nursing/health, translational research, thoracic surgery, staging, and tobacco control. Dr. Wang Jie from the Cancer Hospital Chinese Academy of Medical Sciences was awarded the 2023 Small Cell Lung Cancer Heine H. Hansen Lectureship Award for her outstanding contributions to small cell lung cancer research and treatment.
WCLC 2023 | Dr. Ramalingam Shares Wining Statement as a Winner of the IASLC Scientific Award

WCLC 2023 | Dr. Ramalingam Shares Wining Statement as a Winner of the IASLC Scientific Award

2024.01.19
The Paul A. Bunn, Jr. Scientific Award, bestowed by IASLC, aims to honor the lifelong scientific contributions of IASLC scientists to thoracic cancer research. Dr. Ramalingam's research focuses on developing new treatment strategies for lung cancer patients. His team developed innovative treatment regimens for lung cancer patients with EGFR mutations, which led to the FDA's approval of a third-generation EGFR inhibitor for metastatic non-small cell lung cancer. Additionally He also led clinical and translational research on new immunotherapies for treating lung cancer , resulting in over 400 published, peer-reviewed publications. He also served on the IASLC board of directors (2017-2021) and the NCI Thoracic Malignancy Steering Committee (2012-2021). He is currently the chief editor of the journal 《Cancer》 published by the American Society of Clinical Oncology.
WCLC 2023 | Dr. Liu:Immunotherapy Combined Chemotherapy Can Bring Long-term Survival Benefits to ES-SCLC Patients

WCLC 2023 | Dr. Liu:Immunotherapy Combined Chemotherapy Can Bring Long-term Survival Benefits to ES-SCLC Patients

2024.01.19
The 2023 World Conference on Lung Cancer (WCLC), organized by the International Association for the Study of Lung Cancer (IASLC), took place in Singapore from September 9th to 12th. Dr. Stephen V. Liu from Georgetown University presented an important study (Abstract No: OA01.04) on the long-term follow-up results of first-line immunotherapy combined with chemotherapy in ES-SCLC patients. Oncology Frontier invited Dr. Liu to highlight his presentation at the conference.
WCLC Live | Dr. Johnson: ADC Targeting B7-H3 Demonstrates Effective and Durable Response in Refractory SCLC Patients

WCLC Live | Dr. Johnson: ADC Targeting B7-H3 Demonstrates Effective and Durable Response in Refractory SCLC Patients

2024.01.19
The 2023 World Conference on Lung Cancer (WCLC), organized by the International Association for the Study of Lung Cancer (IASLC), took place in Singapore from September 9-12. Dr. Melissa L. Johnson from Northwestern University's Feinberg School of Medicine presented pivotal findings on antibody-drug conjugates (ADC) for treating small cell lung cancer (SCLC). We had the privilege to interview Dr. Johnson during the conference. Here are the highlights:
Dr. Wu Yilong, Dr. Cheng Ying, and Dr.Han Baohui Discuss the latest advancements in Small Cell Lung Cancer Research and Analyze the Development of ADC

Dr. Wu Yilong, Dr. Cheng Ying, and Dr.Han Baohui Discuss the latest advancements in Small Cell Lung Cancer Research and Analyze the Development of ADC

2024.01.19
For the first time in three years, Chinese experts were able to participated in the WCLC conference in person, following the end of the impact of the COVID-19 pandemic , engaging in face-to-face discussions with international scholars. Dr. Wu Yilong, Dr. Cheng Ying, and Dr. Han Baohui shared their experiences of attending the conference in Singapore.
ASCO China Voice | Professor Wu Yilong Reports Phase III EVEREST Trial Results at ASCO

ASCO China Voice | Professor Wu Yilong Reports Phase III EVEREST Trial Results at ASCO

2023.11.27
The American Society of Clinical Oncology (ASCO) Annual Meeting was held in Chicago from June 2 to June 6, 2023. Oncology Insight delves into the forefront of the conference, inviting researchers to share the most prominent Chinese research at ASCO, witnessing the advancement of China's anti-tumor efforts on the international stage. Professor Wu Yilong from the People's Hospital of Guangdong Province presented the results of the Phase III EVEREST study at ASCO 2023 in the form of an oral presentation. This article provides specific details of the EVEREST study and invites Professor Wu Yilong to provide an interpretation.